Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2026".

Management guided margin improvementManagement guided margin pressureInvestor Communications View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹322.00

prior close

₹320.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.2% vs market

Healthcare Service Provider peers, median of 26sector-0.4%-4.6% vs sector

On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 4.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.4

10m

-6.4

15m

-6.2

30m

-6.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.1-5.2-0.4-4.6

Next day

-7.5+1.7-9.1-1.3-6.2

-8.4+2.4-10.8-0.6-7.8

-9.9+2.4-12.3+1.8-11.7

-10.2+1.7-12.0+0.2-10.5

-13.0+0.6-13.6-3.0-10.1

-9.2+1.9-11.1-2.1-7.1

15d

-16.2+4.9-21.1-0.6-15.6

-13.5+8.9-22.4+1.1-14.6

-19.6+7.5-27.1-5.5-14.1

-0.0+13.6-13.6+0.7-0.8

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suraksha Diagnostic reported strong top-line growth with FY26 total income rising 23% to ₹3,136 million and EBITDA up 16% to ₹986 million. Test volumes grew 22% to 8.16 million, driven by network expansion adding 2 hubs, 11 spoke centres and 4 PPP projects. However, PAT grew only 1.4% to ₹314 million as PAT margin contracted from 12.3% to 10.1%, reflecting investment costs in new centres. Q4 saw an even sharper contrast with 25% EBITDA growth but 14% PAT decline. CEO Ritu Mittal stated that mature centres over 2 years old operate at a stable 36-37% EBITDA margin, and the company is following an 'Investing for Scale' strategy accepting short-term margin compression for long-term value creation.

Likely market impact

The stock may face short-term pressure as profit growth lags revenue growth, but investors may find comfort in management's guidance that new centres will mature and restore margins to 36-37% levels, similar to established centres.